EVOLUTION IN FRAGILITY IN PEOPLE ON THE WAITING LIST FOR A KIDNEY TRANSPLANT

May 19, 2026 updated by: Anna Bach Pascual, Hospital del Mar

This study looks at how the physical and emotional health of people changes while they wait for a kidney transplant. Waiting for an organ can take a long time. During this period, some patients become "frail." This means they lose strength and are at a higher risk for health problems.

The main goal is to follow these patients over time to better understand their needs. Researchers will use a mobile app to collect information directly from patients about how they feel and their quality of life. The study will also include personal interviews to learn about the patients' experiences and any difficulties they face when using technology.

The results of this study will help to:

  • Identify early which patients are losing strength or health.
  • Improve the support that nurses provide during the transplant waiting period.
  • Make sure that digital health tools are easy for everyone to use. In short, this work aims to help patients reach the day of their surgery in the best possible condition.

Study Overview

Detailed Description

Study Design and Framework This research employs a convergent-parallel mixed-methods design to evaluate frailty dynamics and patient-reported outcomes in kidney transplant (KT) candidates. The quantitative component is a longitudinal observational study, while the qualitative component is grounded in Heideggerian hermeneutic phenomenology to explore the lived experience of patients during the waiting list period.

Quantitative Procedures and Data Collection Participants will be recruited during their initial KT evaluation at Hospital del Mar (Barcelona). Frailty will be assessed using the Fried Phenotype (assessing weight loss, exhaustion, physical activity, walk time, and grip strength) at baseline and subsequently every six months while the patient remains on the waiting list.

To monitor Patient-Reported Outcome Measures (PROMs), the study utilizes the PROMIS-29 v2.0 questionnaire. This instrument covers seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles/activities, and pain interference. Data collection will be performed via a digital platform (ePROMs), allowing for real-time monitoring. For patients facing technological or language barriers, an Advanced Practice Nurse (APN) will provide support to ensure data completeness and minimize selection bias.

Qualitative Exploration A purposive sample of participants will undergo in-depth semi-structured interviews. These sessions will focus on the subjective meaning of frailty, the impact of the waiting period on daily life, and the experience of using digital health tools. Interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis to identify core existential themes.

Quality Assurance and Data Management

  • Data Validation: A data dictionary has been developed, defining each variable, its source, and acceptable ranges to ensure consistency.
  • Source Data Verification: Data entered into the electronic Case Report Form (eCRF) will be cross-referenced with electronic medical records to ensure accuracy.
  • Standard Operating Procedures (SOPs): Specific SOPs are in place for patient recruitment, the standardized administration of physical performance tests (e.g., handgrip strength using a dynamometer), and the management of technical issues with the ePROM platform.

Statistical Analysis Plan (SAP) Quantitative data will be analyzed using SPSS v.25. Descriptive statistics will summarize baseline characteristics. Longitudinal changes in frailty scores and PROMs will be analyzed using linear mixed models or generalized estimating equations (GEE) to account for repeated measures. The relationship between frailty status and health-related quality of life (HRQoL) will be assessed using correlation coefficients and multivariate regression models adjusted for age, comorbidity, and time on dialysis.

Missing Data Plan The study aims to minimize missing data through APN-led follow-up. If data are missing at random, multiple imputation techniques will be considered. For patients unable to use digital tools, paper-based alternatives or assisted entry will be provided to reduce non-response bias.

Sample Size Assessment The sample size is based on the prevailing activity of the kidney transplant unit, aiming to include all eligible candidates over the recruitment period (estimated N ≈ 150-200) to ensure sufficient power for detecting longitudinal changes in frailty prevalence and its association with PROMs.

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Anna Bach Pascual, RN, MSN i PhDc
  • Phone Number: +34 648653656
  • Email: abach@hmar.cat

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients with end-stage renal disease (ESRD) managed at the Nephrology Department of Hospital del Mar (Barcelona). This includes patients receiving renal replacement therapy (hemodialysis or peritoneal dialysis) or those in the pre-dialysis stage who have been referred for kidney transplant evaluation. The population is characterized by a high burden of comorbidity and varying degrees of physical frailty associated with chronic uremia and long-term dialysis treatment.

Description

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Diagnosed with Chronic Kidney Disease (CKD) Stage 5.
  • Currently undergoing clinical evaluation for kidney transplantation on the deceased-donor kidney transplant waiting list at Hospital del Mar.
  • Ability to understand and provide written informed consent.
  • Ability to use or have access to a digital device (smartphone/tablet) for ePROM completion.

Exclusion Criteria:

  • Severe cognitive impairment or psychiatric disorders that prevent the reliable completion of questionnaires or physical tests.
  • Major physical disability that precludes the assessment of gait speed or handgrip strength (e.g., bilateral leg amputation or severe hand deformity).
  • Acute medical condition requiring hospitalization at the time of enrollment (assessment can be deferred).
  • Language barrier that prevents understanding the study or the qualitative interview.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Kidney Transplant Candidates

This is a single-group observational cohort of adult patients with Stage 5 Chronic Kidney Disease (CKD) who are undergoing evaluation for or are already active on the deceased-donor kidney transplant waiting list.

The nature of this group is characterized by the transition from advanced chronic illness to potential transplantation. All participants will undergo a longitudinal follow-up (every 6 months) to monitor frailty status and health-related quality of life. The study focuses on the "frailty dynamics" during the waiting period.

Data collection includes:

Physical assessments (Fried Phenotype: handgrip strength, gait speed).

Patient-Reported Outcome Measures (PROMs) via the PROMIS-29 digital platform (ePROMs).

Qualitative hermeneutic interviews for a selected subset to explore the lived experience of frailty.

No clinical intervention or medication will be administered as part of this study protocol.

Intervention Description (Intervention 1: Frailty Assessment) Systematic multidimensional assessment of frailty conducted by an Advanced Practice Nurse (APN) specialized in nephrology.

Components of assessment:

  1. Fried Phenotype: Objective measurement of 5 criteria: unintended weight loss, self-reported exhaustion, level of physical activity, gait speed (measured over 4 meters), and handgrip strength (measured using a calibrated hydraulic dynamometer).
  2. Clinical Frailty Scale (CFS): Global clinical judgment based on fitness and functional independence.
  3. SPPB (Short Physical Performance Battery): To assess balance, gait, and lower limb strength (chair stands).

Frequency: Assessments will be performed at baseline (enrollment) and every 6 months (+/- 1 month) throughout the duration of the patient's presence on the kidney transplant waiting list.

All measurements follow standardized protocols to minimize inter-observer variability and ensure data reproducibility.

Other Names:
  • Fried Frailty Phenotype Assessment
  • Physical Performance Monitoring
  • Comprehensive Frailty Evaluation
  • Clinical Frailty Scale (CFS)

Implementation of a digital health strategy to monitor patient-reported outcomes throughout the kidney transplant waiting list period.

Core Instrument: Participants will complete the PROMIS-29 v2.0 (Patient-Reported Outcomes Measurement Information System) questionnaire. This validated tool assesses 7 key health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Roles/Activities, and Pain Interference, plus a single-item pain intensity scale.

Procedure:

  1. Data Collection: Administered via a secure digital platform (ePROMs) accessible via smartphone, tablet, or computer.
  2. Frequency: Data will be collected at baseline and subsequently every 6 months, coinciding with clinical frailty assessments.
  3. Support: An Advanced Practice Nurse (APN) provides technical onboarding and follows up on non-compliance to ensure data completeness and address the digital divide.

This intervention is purely observational and aimed at capturing the patient's subjectiv

Other Names:
  • PROMIS-29 v2.0 Questionnaire
  • Digital Health Monitoring
  • Patient-Reported Quality of Life Assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Frailty Status (Fried Phenotype)
Time Frame: Baseline, 6 months, 12 months

Frailty is assessed using the Fried Phenotype, which includes five criteria: unintended weight loss, self-reported exhaustion, low physical activity, slow gait speed (4-meter walk test), and weak grip strength (measured by a hydraulic dynamometer).Scoring: Each criterion is scored 0 (absent) or 1 (present).

Non-frail: 0 points Pre-frail: 1-2 points Frail: 3-5 points

The primary outcome is the longitudinal change or transition between these categories during the waiting list period.

Baseline, 6 months, 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Health-Related Quality of Life (HRQoL)
Time Frame: Baseline, 6 months, 12 months

Assessed using the PROMIS-29 v2.0 questionnaire. This tool measures 7 domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference.

Scoring: Each domain is scored on a T-score metric, where 50 is the mean of the relevant reference population (SD = 10). Higher scores represent more of the concept being measured (e.g., higher anxiety, better physical function).

Baseline, 6 months, 12 months
Clinical Transitions on the Waiting List
Time Frame: 12 Months

Incidence of major clinical events that alter the patient's status.

Events monitored: Successful kidney transplantation, removal from the waiting list due to clinical worsening, or death while on the list.

12 Months
Digital Tool Usability and Barriers
Time Frame: 12 months
Evaluation of the feasibility and barriers to using the ePROM platform. Assessment: Measured through the completion rate of the digital questionnaires and the qualitative feedback regarding technological challenges or the "digital divide" as identified during APN follow-up.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

May 19, 2026

First Submitted That Met QC Criteria

May 19, 2026

First Posted (Actual)

May 26, 2026

Study Record Updates

Last Update Posted (Actual)

May 26, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared at this time to protect the confidentiality of the participants and the integrity of the ongoing doctoral thesis. The data collected involves sensitive clinical information and qualitative interviews within a specific, small-scale clinical setting (kidney transplant waiting list).

However, the study results will be disseminated through peer-reviewed publications and conference presentations. Requests for access to aggregate data or specific methodological details can be directed to the Principal Investigator and will be considered on a case-by-case basis, subject to approval by the Institutional Review Board (CEIm) and in compliance with the General Data Protection Regulation (GDPR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Longitudinal Frailty Assessment

Subscribe